Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Triple Flag Precious Metals Q1 2026 Earnings Call - Record Start Driven by High-Margin Cash Flow and Accretive U.S. Copper Royalty
Triple Flag Precious Metals delivered a historic first quarter, shattering records across every key metric with 30,000+ GEOs, $129 million in adjusted EBITDA, and a 67% surge in operating cash flow pe...
- Q1 2026 marks the strongest quarter in company history across every key metric, including over 30,000 GEOs, $129 million in adjusted EBITDA, and $0.55 in operating cash flow per share.
- Operating cash flow per share surged 67% year-over-year, driven by high-margin exposure to rising gold and silver prices and the model functioning as intended.
- The company unlocked the high-grade E44 gold deposit at Northparkes, securing guaranteed minimum deliveries over seven years starting in 2030, aligning with Evolution Mining's block cave and mill expansion plans.
- +8 more takeaways
CVS Health Q1 2026 Earnings Call - EPS Guidance Raised to $7.30-$7.50 as Aetna Margins Recover
CVS Health delivered a strong first quarter, driving a 14% year-over-year increase in adjusted earnings per share to $2.57. The company responded to this momentum by raising its full-year 2026 adjuste...
- Adjusted EPS of $2.57 beat expectations, driving a full-year 2026 guidance raise to $7.30-$7.50, up from $7.00-$7.20.
- Revenue surged over 6% year-over-year to $100 billion, with adjusted operating income increasing 12% to $5.2 billion.
- Aetna’s medical benefit ratio improved to 84.6% in Q1, reflecting strong medical cost management and favorable prior year development.
- +12 more takeaways
LivaNova PLC Q1 2026 Earnings Call - OSA FDA Approval and Epilepsy Reimbursement Tailwind Drive Upgraded Guidance
LivaNova delivered a strong first quarter, posting 11% constant currency revenue growth driven by durable performance in its cardiopulmonary and epilepsy segments. The company raised its full-year 202...
- LivaNova reported Q1 2026 revenue of $362 million, an 11% increase on a constant currency basis, driven by strength across all regions and both core businesses.
- Full-year 2026 revenue growth guidance was raised to 7%-8%, up from 6%-7%, aligning with the high end of the company’s 2025-2028 growth framework.
- Cardiopulmonary revenue grew 14% in Q1, with heart-lung machine revenue in the high teens and consumables in the mid-teens, supported by Essenz placements and market share gains.
- +7 more takeaways
NACCO Industries Q1 2026 Earnings Call - Strong Profit Growth Driven by Utility Coal and New Infrastructure Contracts
NACCO Industries delivered a robust start to 2026, with first-quarter operating profit jumping 43% year-over-year and adjusted EBITDA rising 28%. The gains were anchored by improved efficiency at Miss...
- First-quarter operating profit surged 43% year-over-year and 45% sequentially, with adjusted EBITDA up 28% year-over-year to $16.4 million.
- Mississippi Lignite Mining Company drove utility coal segment strength, with operating profit doubling year-over-year to $7.4 million as cost per ton fell and reclamation activities offset reduced deliveries during a power plant outage.
- Contract mining revenues jumped 32% year-over-year, fueled by the commencement of a multi-year dragline services contract for the U.S. Army Corps of Engineers in Florida and increased limestone deliveries.
- +7 more takeaways
CS Disco Q1 2026 Earnings Call - AI Platform Launch Drives Revenue Beat and Margin Expansion
CS Disco delivered a strong Q1 2026, beating revenue and adjusted EBITDA guidance as the launch of the all-in-one DISCO Platform and deepening AI adoption accelerated growth. Total revenue rose 14% ye...
- Total revenue grew 14% year-over-year to $41.9 million, beating the high end of guidance.
- Software revenue increased 12% to $34.7 million, marking the fourth consecutive quarter of accelerating growth.
- Adjusted EBITDA improved 600 basis points to a negative $3.5 million, outperforming the high end of guidance.
- +7 more takeaways
Acushnet Company Q1 2026 Earnings Call - Accelerated GTS Driver Launch and Tariff Uncertainty Offset by Strong Equipment Growth
Acushnet delivered a solid first quarter, with net sales rising 5% constant currency to $753 million and adjusted EBITDA up 4% to $145 million. The results were driven by strong momentum in Titleist g...
- Worldwide net sales increased 5% on a constant currency basis to $753 million in Q1 2026.
- Adjusted EBITDA rose 4% year-over-year to $145 million, up $6 million from Q1 2025.
- Titleist golf equipment sales grew 7%, supported by strong demand for balls and clubs.
- +7 more takeaways
Royalty Pharma Q1 2026 Earnings Call - Double-Digit Growth and R&D Co-Funding Surge
Royalty Pharma delivered a robust first quarter, growing portfolio receipts by 10% and recurring royalty receipts by 13%, driven by a diversified portfolio and strong clinical catalysts. Management ra...
- Royalty Pharma reported 10% growth in portfolio receipts and 13% growth in recurring royalty receipts for Q1 2026, demonstrating the resilience of its diversified portfolio.
- Management raised full-year 2026 guidance for portfolio receipts to $3.325 billion–$3.45 billion, up from the previous range of $3.275 billion–$3.425 billion.
- The company announced $1.25 billion in new transactions, including a $250 million upfront investment for a royalty on Ziihera, a HER2-targeted cancer therapy with blockbuster potential in gastric cancer.
- +9 more takeaways
SolarEdge Q1 2026 Earnings Call - Transitioning to Offensive Growth with Near-Break-Even Results and Strategic Shifts
SolarEdge delivered a pivotal Q1 2026 report that underscores a decisive shift from defensive cost-cutting to offensive growth, marked by 46% year-over-year revenue expansion and a clear path to near-...
- Q1 revenue surged 46% year-over-year to $310 million, marking the fifth consecutive quarter of growth without significant revenue pull-forward.
- Management guided for Q2 revenue between $325-$355 million, with a midpoint EBIT loss of approximately $3.5 million, signaling a near-break-even milestone.
- Non-GAAP gross margin expanded slightly to 23.5%, driven by a favorable product mix and lower seasonal warranty costs, while operating expenses came in well below guidance.
- +7 more takeaways
CVG Q1 2026 Earnings Call - Electrical Systems Momentum Offsets Class 8 Weakness
CVG delivered a mixed first quarter, with revenue growth and margin expansion in its Global Electrical Systems and Global Seating segments partially offset by a sharp pullback in Trim Systems. The com...
- Revenue reached $171.5 million, up slightly from $169.8 million in Q1 2025, driven by strength in Global Electrical Systems and Global Seating.
- Global Electrical Systems revenue surged 14% year-over-year to $57.4 million, fueled by new business wins and the production ramp for the Zoox autonomous vehicle program.
- Global Seating revenue grew 1.5% to $74.5 million, supported by higher international volumes and a 20% increase in aftermarket orders.
- +7 more takeaways
Madrigal Pharmaceuticals Q1 2026 Earnings Call - Rezdiffra Hits $1.1B Run Rate as MASH Market Expands 50%
Madrigal Pharmaceuticals delivered a commanding first quarter, with Rezdiffra net sales surging 127% year-over-year to $311 million and trailing twelve-month revenue crossing the $1.1 billion mark. Th...
- 1. Rezdiffra net sales surged 127% year-over-year to $311 million in Q1 2026, with trailing twelve-month revenue exceeding $1.1 billion, confirming blockbuster status.
- 2. The U.S. addressable MASH market grew nearly 50% in two years, expanding from 315,000 to 460,000 diagnosed patients, driven by increased awareness and specialist involvement.
- 3. Active patients on Rezdiffra more than doubled year-over-year, reaching over 42,250, with management noting strong momentum carrying into Q2 2026.
- +7 more takeaways